Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis / image credit:©Calin/AdobeStock
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

September 30th 2025

The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.

Planning to Attend FMX 2025, October 5-9? What Family Physicians Can Expect in Anaheim / image credit ©Anton Gvozdikov/stock.adobe.com
Planning to Attend FMX 2025, October 5-9? What Family Physicians Can Expect in Anaheim

September 29th 2025

Beer, Cider Linked to Higher Risk of Gout: Daily Dose / image credit: ©New Africa/AdobeStock
Beer, Cider Linked to Higher Risk of Gout: Daily Dose

October 22nd 2024

Beer and Cider Associated with Higher Risk of Gout in Both Sexes vs Other Alcohol Types / Image credit: ©David Prahl/AdobeStock
Beer and Cider Associated with Higher Risk of Gout in Both Sexes vs Other Alcohol Types

October 14th 2024

Intervention Cuts Alcohol Use in Youths with Chronic Medical Conditions: Daily Dose / image credit: ©New Africa/AdobeStock
Intervention Cuts Alcohol Use in Youths with Chronic Medical Conditions: Daily Dose

August 7th 2024

Video Interviews
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.